Drug intelligence / Profile preview

methylergonovine + oxytocin

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Intramuscular, Oral

Overview

A combination of two uterotonic agents used to prevent and control postpartum hemorrhage. Methylergonovine is an ergot alkaloid that acts directly on the smooth muscle of the uterus to increase tone, rate, and amplitude of rhythmic contractions. Oxytocin stimulates uterine contractions and helps the uterus return to its normal size after childbirth. The combination has an additive or synergistic effect in preventing postpartum hemorrhage compared to oxytocin alone.

Brand names: SyntometrineMethergine
Other names: oxytocin + methylergometrine

Targets

HTR2B (5-Hydroxytryptamine Receptor 2B)DRD1 (Dopamine D1 Receptor)ADRA1A (α1A)Oxytocin receptor

Beyond the preview

Go deeper on methylergonovine + oxytocin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylergonovine + oxytocin.

Explore the full profile